(1) Alternative Pathway Device Pass-Through Applications As discussed in the CY 2026 OPPS/ASC proposed rule, we received four device pass-through applications by the March 2025 quarterly application deadline for devices that have received Breakthrough Device designation from FDA and FDA marketing authorization for the indication for which they have a Breakthrough Device designation and, therefore were eligible to apply under the alternative pathway
A word of advice: if you stop taking it or miss a dose, you might start feeling bloated or at least I did
What they did: n = ~ 7,000 adults with obesity and high CV risk
By selectively activating amylin receptors involved in satiety and energy balance, Cagrilintide supports research into glucose regulation, caloric intake modulation, and sustained metabolic signaling
This depends on the dose and how much water was added: 5mg vial at 250mcg/dose = 20 doses 5mg vial at 500mcg/dose = 10 doses 10mg vial at 250mcg/dose = 40 doses 10mg vial at 500mcg/dose = 20 doses At the community-reported common protocol of 250mcg twice daily, a 5mg vial lasts 10 days
They make sense conceptually but need clinical trials to determine safety, dosage, timing and interactions
